NEW YORK (GenomeWeb News) – The combined businesses of Hologic and Gen-Probe posted $1.88 billion in revenues through the first nine months of Fiscal Year 2012 on a pro forma basis, Hologic said after the close of the market on Monday.
In a document filed with the US Securities and Exchange Commission, Hologic said that it had $1.41 billion in revenues, while Gen-Probe had $467.6 million in revenues through June 23, 2012. Bedford, Mass.-based Hologic, which acquired Gen-Probe for $3.8 billion in August, ended its fiscal year in late September and is scheduled to announce its fiscal fourth-quarter and full fiscal-year 2012 earnings results on Nov. 12.
For the first nine months of fiscal 2012, the combined company had a net loss of $102.1 million, or $.39 per share, on a pro forma basis. R&D costs totaled $170.5 million, and SG&A costs were $463.2 million.
Reporting as if Gen-Probe were part of Hologic in full Fiscal Year 2011 ended Sept. 24, 2011, Hologic said that revenues for the combined company were $2.37 billion on a pro forma basis. Hologic had $1.79 billion in revenues and Gen-Probe had $576.2 million in revenues.
The combined firm's net loss was $23.8 million, or $.09 per share.
Its R&D expenses were $231.6 million, while SG&A costs were $575.9 million.
The combined firm exited the quarter ended June 23, 2012 with $471.6 million in cash and cash equivalents on a pro forma basis.